A great deal of experimental evidence have indicated that the over-expression of the extracellular serine protease urokinase-plasminogen activator (uPa) and its receptor uPAR actively contributes to the aggressive phenotype of a number of cancers, and anti-uPaR antagonistic antibodies have been proven successful in reducing TNBC growth in vivo [4]. The gene discussed is PLAUR; the disease is cancer.